OBJECTIVE: To estimate the efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC), using a meta-analysis of randomized controlled trials. METHODS: A literature search for randomized clinical trials (RCTs) was performed through Pubmed, Embase, and Web of Science (up to May 22, 2014). The outcome measures were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events. Two investigators identified eligible studies and extracted data independently. The quality of the included studies was assessed by the Jadad score. Hazard ratios (HR), risk ratio (RR), and 95% confidence intervals (Cls) were calculated and pooled. RESULTS: A total of 4 RCTs with 2069 patients were included in this meta-analysis. The addition of bevacizumab to cetuximab- or panitumumab-based therapy did not significantly prolonged PFS, when compared with antibody alone. The subgroup analysis of adding bevacizumab to cetuximab-based therapy also suggested no significant benefit in PFS or in OS. Patients who received the combined therapy did not have a higher ORR (RR = 0.98, 95% CI: 0.89-1.07; P = 0.608). The incidence of grade 3/4 adverse events was not significantly higher in the bevacizumab and cetuximab/panitumumab group. CONCLUSION: The addition of bevacizumab to cetuximab- or panitumumab-based therapy did not improve PFS and OS resulting in better ORR. Thus, the combined therapy of bevacizumab with cetuximab or panitumumab is not recommended for the treatment of mCRC. However, larger scale RCTs are needed to confirm these findings.
OBJECTIVE: To estimate the efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC), using a meta-analysis of randomized controlled trials. METHODS: A literature search for randomized clinical trials (RCTs) was performed through Pubmed, Embase, and Web of Science (up to May 22, 2014). The outcome measures were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events. Two investigators identified eligible studies and extracted data independently. The quality of the included studies was assessed by the Jadad score. Hazard ratios (HR), risk ratio (RR), and 95% confidence intervals (Cls) were calculated and pooled. RESULTS: A total of 4 RCTs with 2069 patients were included in this meta-analysis. The addition of bevacizumab to cetuximab- or panitumumab-based therapy did not significantly prolonged PFS, when compared with antibody alone. The subgroup analysis of adding bevacizumab to cetuximab-based therapy also suggested no significant benefit in PFS or in OS. Patients who received the combined therapy did not have a higher ORR (RR = 0.98, 95% CI: 0.89-1.07; P = 0.608). The incidence of grade 3/4 adverse events was not significantly higher in the bevacizumab and cetuximab/panitumumab group. CONCLUSION: The addition of bevacizumab to cetuximab- or panitumumab-based therapy did not improve PFS and OS resulting in better ORR. Thus, the combined therapy of bevacizumab with cetuximab or panitumumab is not recommended for the treatment of mCRC. However, larger scale RCTs are needed to confirm these findings.
Authors: Raymond C Wadlow; Aram F Hezel; Thomas A Abrams; Lawrence S Blaszkowsky; Charles S Fuchs; Matthew H Kulke; Eunice L Kwak; Jeffrey A Meyerhardt; David P Ryan; Jackie Szymonifka; Brian M Wolpin; Andrew X Zhu; Jeffrey W Clark Journal: Oncologist Date: 2011-12-30
Authors: David R Spigel; F Anthony Greco; David Waterhouse; Dianna Shipley; Cassie M Lane; Elizabeth R Vazquez; Bobby L Clark; Jeffrey R Infante; Johanna C Bendell; Howard A Burris; John D Hainsworth Journal: Clin Adv Hematol Oncol Date: 2010-07
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Jordan Berlin; James Posey; Simon Tchekmedyian; Eddie Hu; David Chan; Imtiaz Malik; Liqiang Yang; Rafael G Amado; J Randolph Hecht Journal: Clin Colorectal Cancer Date: 2007-03 Impact factor: 4.481
Authors: Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Allen Lee Cohn; Takayuki Yoshino; Volker Heinemann; Radka Obermannova; György Bodoky; Jana Prausová; Rocio Garcia-Carbonero; Tudor Ciuleanu; Pilar Garcia-Alfonso; David C Portnoy; Eric Van Cutsem; Kentaro Yamazaki; Philip R Clingan; Jonathon Polikoff; Sara Lonardi; Lisa M O'Brien; Ling Gao; Ling Yang; David Ferry; Federico Nasroulah; Josep Tabernero Journal: Cancer Chemother Pharmacol Date: 2017-07-25 Impact factor: 3.333
Authors: Wânia Cristina da Silva; Vânia Eloisa de Araujo; Ellias Magalhães E Abreu Lima; Jessica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Paulo Henrique Ribeiro Fernandes Almeida; Francisco de Assis Acurcio; Brian Godman; Amanj Kurdi; Mariângela Leal Cherchiglia; Eli Iola Gurgel Andrade Journal: BioDrugs Date: 2018-12 Impact factor: 5.807